Advisory Research’s Pacific Biosciences PACB Stock Holding History

Advisory Research’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-23,455	Closed	-$312K	–	466
2023 Q2	$312K	Buy	+23,455	New	+$285K	0.04%	370
2021 Q3	–	Sell	-71,363	Closed	-$2.5M	–	398
2021 Q2	$2.5M	Buy	71,363 +29,719	+71%	+$864K	0.16%	120
2021 Q1	$1.39M	Buy	41,644 +20,448	+96%	+$716K	0.1%	170
2020 Q4	$550K	Sell	21,196 -1,915	-8%	-$32.5K	0.04%	252
2020 Q3	$228K	Buy	+23,111	New	+$133K	0.02%	288

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Advisory Research's PACB Position: Q3 2023 in Review

Advisory Research sold out of Pacific Biosciences (PACB) in Q3 2023, closing a stake of 23,455 shares — an estimated $312K sold.

Advisory Research first reported a position in PACB in Q3 2020 and held it in 5 quarters. The position peaked at $2.5M in Q2 2021. 274 funds tracked by Wall St. Rank hold PACB as of Q3 2023.

Advisory Research reported no remaining Pacific Biosciences position as of Q3 2023 after selling out during the quarter.
Advisory Research sold 23,455 Pacific Biosciences shares in Q3 2023, an estimated $312K.
Advisory Research first reported a position in Pacific Biosciences in Q3 2020 and held it in 5 quarters.
Advisory Research's Pacific Biosciences position peaked at $2.5M in Q2 2021.
274 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2023.

Based on Advisory Research's 13F filing for Q3 2023, filed 13 Nov 2023.